問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Taipei Medical University Hospital (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Digestive System Department

Division of General Internal Medicine

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Thoracic Medicine

更新時間：2023-09-19

邱昭華Chiu, Chao-Hua
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • chaohuachiu@tmu.edu.tw

Recruiting Trial

103Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱昭華

List

195Cases

2014-09-30 - 2020-02-21

Phase III

Completed
A Randomized, Open Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

  • Condition/Disease

    non-squamous Non-Small Cell Lung Cancer.

  • Test Drug

    Veliparib (ABT-888)

Participate Sites
5Sites

Terminated5Sites

2024-05-01 - 2032-02-29

Phase II

Active
A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) – LIVIGNO-4

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    N/A N/A

Participate Sites
4Sites

Recruiting4Sites

2018-01-05 - 2021-12-31

Phase I

Active
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors/NSCLC

  • Test Drug

    ABBV-399

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2020-09-20 - 2027-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2022-01-01 - 2025-02-28

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2024-10-01 - 2032-12-31

Phase I

Active
A First-In-Human (FIH) phase I/II open-label, multicentre, dose escalation and expansion trial of VERT-002 in patients with locally advanced or metastatic solid tumors including non-small cell lung cancer (NSCLC) harboring MET alterations.

  • Condition/Disease

    non-small cell lung cancer (NSCLC)

  • Test Drug

    injection

Participate Sites
3Sites

Recruiting3Sites

2020-12-01 - 2024-10-01

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2018-12-01 - 2026-03-31

Phase I

Completed
A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)

  • Condition/Disease

    Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    皮下注射劑 注射劑 注射劑 注射劑 注射劑

Participate Sites
8Sites

Recruiting8Sites

2024-04-30 - 2027-04-30

Phase I

Active
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

  • Condition/Disease

    Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    tablet

Participate Sites
5Sites

Recruiting5Sites

2017-01-01 - 2024-06-12

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 3 4 5 6 7 20
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB